Drug Type Small molecule drug |
Synonyms ADD-417090, JBPOS 0101, JBPOS0101 |
Target |
Mechanism mGluRs antagonists(Metabotropic glutamate receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC10H12ClNO3 |
InChIKeyTZOWVYPYWJLZTK-IMTBSYHQSA-N |
CAS Registry1353949-71-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 2 | KR | 30 Jan 2022 | |
Status Epilepticus | Phase 2 | KR | 30 Jan 2022 | |
Spasms, Infantile | Phase 2 | US | 15 Apr 2020 | |
Spasms, Infantile | Phase 2 | KR | 15 Apr 2020 | |
Depression, Postpartum | Phase 1 | KR | 30 Jan 2022 | |
Parkinson Disease | Phase 1 | KR | 30 Jan 2022 | |
Epilepsy | IND Approval | CN | 08 Sep 2022 |
Phase 2 | 16 | hnnyvirqhg(dcmlaukwzu) = ndyrvziqgi nnccixmcvw (fbophhudcu, wvfxuorcxr - lmhwphaagd) View more | - | 16 Feb 2023 |